By Jason Derry --
Trellis Bioscience, Inc. has
announced an agreement with PDL BioPharma, Inc. relating to
discovering monoclonal antibodies that recognize a PDL antigen. Under the agreement, Trellis will utilize its
CellSpot technology to screen for hybridomas that produce antibodies of
interest. Once particular hybridomas are
identified, PDL BioPharma will attempt to develop and commercialize the
antibodies or products relating to the antibodies. Specific details about the agreement, such as
which antigens will be examined or payment structure, were not available.
Jason Derry, Ph.D., who graduated with honors from DePaul University
College of Law, is a molecular biologist and founding author of Patent Docs.
Comments